keyword
MENU ▼
Read by QxMD icon Read
search

iv iron sucrose

keyword
https://www.readbyqxmd.com/read/29680173/iron-deficiency-in-chronic-and-acute-heart-failure-a-contemporary-review-on-intertwined-conditions
#1
REVIEW
Gonçalo J L Cunha, Bruno M L Rocha, Luiz Menezes Falcão
Iron Deficiency (ID) is increasingly recognized as a prevalent comorbid condition in Heart Failure (HF). Despite this, the pathophysiological mechanisms for progressive ID in either chronic or acute HF are still poorly understood. Beyond the traditional factors for iron deficit in the general population, we ought to review the specificities of such paucity in the HF patient, particularly focusing on the interplay between heightened inflammation, overactivity of the sympathetic nervous system and the so-called cardio-renal-anaemia-ID syndrome...
April 18, 2018: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/29669068/adverse-reactions-after-intravenous-iron-infusion-among-inflammatory-bowel-disease-patients-in-the-united-states-2010-2014
#2
Eboselume Akhuemonkhan, Alyssa Parian, Kathryn A Carson, Susan Hutfless
Background: Anemia is a frequent complication of Crohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD). Intravenous (IV) iron is recommended as the initial therapy for patients with clinically active IBD, severe anemia, and intolerance to oral iron. IV iron is associated with serious adverse effects including a black box warning for anaphylaxis with iron dextran and ferumoxytol. We aimed to examine the occurrence of adverse reactions including anaphylaxis after IV iron infusions in a large database of US IBD patients...
April 13, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29599970/medication-practice-in-hospitals-are-nanosimilars-evaluated-and-substituted-correctly
#3
Josefien Knoeff, Beat Flühmann, Stefan Mühlebach
Introduction: This study investigates the drug selection and dispensing behaviour of hospital pharmacists of intravenous iron products including iron sucrose and iron sucrose similar, with special emphasis on substitution and interchangeability in France and Spain. Iron-carbohydrate complex drugs represent different available intravenous iron drugs and are part of the non-biological complex drug (NBCD) class, an expanding drug class with up to 30 brands available in intravenous pharmacotherapy and over 50 in clinical development...
March 2018: European Journal of Hospital Pharmacy. Science and Practice
https://www.readbyqxmd.com/read/29582437/red-blood-cell-transfusion-after-a-global-strategy-for-early-detection-and-treatment-of-iron-deficiency-anemia-three-year-results-of-a-prospective-observational-study
#4
Miguel Angel de Las Nieves Lopez, Ana Maria Matas Cobos, Francisco Sarria Gonzalez, Maria Jose Dominguez Lomeña, Ana Maria Palomo Hernandez, Encarnación Gil Gines, Salvador Serna Juan, Javier Ampuero Ampuero, Antonio Marin Fernandez, Antonia Vazquez de la Villa
BACKGROUND: Anemia is the main indication for red blood cell (RBC) transfusion and iron deficiency is the most prevalent, preventable, and treatable cause of anemia worldwide. We aimed to assess the impact of iron deficiency anemia (IDA) on RBC transfusion by means of a program for prevention, early detection, and treatment. STUDY DESIGN AND METHODS: A prospective observational study was conducted starting in 2014 after an intervention in clinical practice in Melilla, a peripheral city isolated by 207 km sea distance to nearest continental Spain...
March 26, 2018: Transfusion
https://www.readbyqxmd.com/read/29520555/financial-impact-of-intravenous-iron-treatments-on-the-management-of-anaemia-inpatients-a-1-year-observational-study
#5
Amina Delpeuch, Marc Ruivard, Armand Abergel, Olivier Aumaitre, Stéphane Boisgard, Sandrine Bagel, Valérie Sautou
Background Intravenous (IV) iron preparations bypass the difficulties (malabsorption and side effects) associated with oral iron for the treatment of iron deficiency anaemia (IDA). Ferric carboxymaltose (FCM) can be administered as a single infusion over short periods of time but is more expensive than iron sucrose (IS) when the patients are hospitalized. Objectives To evaluate the appropriateness of FCM prescriptions and to establish the economic impact of this management (including disease coding) compared to the use of IV IS...
March 8, 2018: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/29466169/-selection-of-optimal-therapy-at-correction-of-the-anemic-syndrome-in-patients-with-chronic-heart-failure
#6
K K Zahidova
PURPOSE: to study efficacy of various schemes of therapy of patients with chronic heart failure (CHF) and anemia. MATERIALS AND METHODS: We included in this study 208 patients with CHF of ishemic etiology (mean age 60.6±1.4 years, 174 with and 34 without anemia). According to therapeutic regimen of the use of methoxy polyethylene glycol-epoetin beta (MEB, 0.60 mсg/kg) and intravenous (IV) iron hydroxide sucrose complex all patients were divided into 4 groups. In all patients before and after treatment we determined Hb, Ht, plasma levels of ferritin, erythropoietin (EPO), NT-proBNP, IL-1, IL-6, TNF-α, transferrin saturation (TS), total vascular peripheral resistance, and parameters of systolic and diastolic function of left ventricular (LV) myocardium (by echocardiography and doppler echocardiography)...
January 2018: Kardiologiia
https://www.readbyqxmd.com/read/29454888/bioequivalence-decision-for-nanoparticular-iron-complex-drugs-for-parenteral-administration-based-on-their-disposition
#7
Julia Schnorr, Sören Fütterer, Karsten Spicher, Maria Catarinolo, Christoph Schlösser, Harald Enzmann, Peter Langguth
Although parenteral iron products have been established to medicinal use decades before, their structure and pharmacokinetic properties are not fully characterized yet. With its' second reflection paper on intravenous iron-based nano-colloidal products (EMA/CHMP/SWP/620008/2012) the European Medicine Agency provided an extensive catalogue of methods for quality, non-clinical and pharmacokinetic studies for the comparison of nano-sized iron products to an originator (EMA, 2015). For iron distribution studies, the reflection paper assumed the use of rodents...
April 2018: Regulatory Toxicology and Pharmacology: RTP
https://www.readbyqxmd.com/read/29425576/evidence-based-and-consensus-clinical-practice-guidelines-for-the-iron-treatment-of-restless-legs-syndrome-willis-ekbom-disease-in-adults-and-children-an-irlssg-task-force-report
#8
Richard P Allen, Daniel L Picchietti, Michael Auerbach, Yong Won Cho, James R Connor, Christopher J Earley, Diego Garcia-Borreguero, Suresh Kotagal, Mauro Manconi, William Ondo, Jan Ulfberg, John W Winkelman
BACKGROUND: Brain iron deficiency has been implicated in the pathophysiology of RLS, and current RLS treatment guidelines recommend iron treatment when peripheral iron levels are low. In order to assess the evidence on the oral and intravenous (IV) iron treatment of RLS and periodic limb movement disorder (PLMD) in adults and children, the International Restless Legs Syndrome Study Group (IRLSSG) formed a task force to review these studies and provide evidence-based and consensus guidelines for the iron treatment of RLS in adults, and RLS and PLMD in children...
January 2018: Sleep Medicine
https://www.readbyqxmd.com/read/29304848/effectiveness-and-safety-of-ferric-carboxymaltose-compared-to-iron-sucrose-in-women-with-iron-deficiency-anemia-phase-iv-clinical-trials
#9
Amreen Naqash, Rifat Ara, Ghulam N Bader
BACKGROUND: Iron deficiency anemia (IDA) is a significant problem worldwide particularly in women. The aim of the study was to evaluate the effectiveness and safety of intravenous ferric carboxymaltose (FCM) in comparison to iron sucrose (IS) in women with IDA. METHOD: Two hundred patients at Department of Obstetrics and Gynaecology, Sher-i-Kashmir Institute of Medical Sciences Medical College and Hospital, Jammu & Kashmir, India identified with IDA were enrolled for the study...
January 5, 2018: BMC Women's Health
https://www.readbyqxmd.com/read/29303999/comparative-evaluation-of-u-s-brand-and-generic-intravenous-sodium-ferric-gluconate-complex-in-sucrose-injection-physicochemical-characterization
#10
Dajun Sun, Rodney Rouse, Vikram Patel, Yong Wu, Jiwen Zheng, Alokita Karmakar, Anil K Patri, Priyanka Chitranshi, David Keire, Jia Ma, Wenlei Jiang
The objective of this study was to evaluate physicochemical equivalence between brand (i.e., Ferrlecit) and generic sodium ferric gluconate (SFG) in sucrose injection by conducting a series of comparative in vitro characterizations using advanced analytical techniques. The elemental iron and carbon content, thermal properties, viscosity, particle size, zeta potential, sedimentation coefficient, and molecular weight were determined. There was no noticeable difference between brand and generic SFG in sucrose injection for the above physical parameters evaluated, except for the sedimentation coefficient determined by sedimentation velocity analytical ultracentrifugation (SV-AUC) and molecular weight by asymmetric field flow fractionation-multi-angle light scattering (AFFF-MALS)...
January 5, 2018: Nanomaterials
https://www.readbyqxmd.com/read/29283393/comparative-evaluation-of-u-s-brand-and-generic-intravenous-sodium-ferric-gluconate-complex-in-sucrose-injection-biodistribution-after-intravenous-dosing-in-rats
#11
Christopher R Beekman, Murali Matta, Christopher D Thomas, Adil Mohammad, Sharron Stewart, Lin Xu, Ashok Chockalingam, Katherine Shea, Dajun Sun, Wenlei Jiang, Vikram Patel, Rodney Rouse
Relative biodistribution of FDA-approved innovator and generic sodium ferric gluconate (SFG) drug products was investigated to identify differences in tissue distribution of iron after intravenous dosing to rats. Three equal cohorts of 42 male Sprague-Dawley rats were created with each cohort receiving one of three treatments: (1) the innovator SFG product dosed intravenously at a concentration of 40 mg/kg; (2) the generic SFG product dosed intravenously at a concentration of 40 mg/kg; (3) saline dosed intravenously at equivalent volume to SFG products...
December 28, 2017: Nanomaterials
https://www.readbyqxmd.com/read/29244729/comparative-evaluation-of-u-s-brand-and-generic-intravenous-sodium-ferric-gluconate-complex-in-sucrose-injection-in-vitro-cellular-uptake
#12
Min Wu, Dajun Sun, Katherine Tyner, Wenlei Jiang, Rodney Rouse
Iron deficiency anemia is a common clinical consequence for people who suffer from chronic kidney disease, especially those requiring dialysis. Intravenous (IV) iron therapy is a widely accepted safe and efficacious treatment for iron deficiency anemia. Numerous IV iron drugs have been approved by U.S. Food and Drug Administration (FDA), including a single generic product, sodium ferric gluconate complex in sucrose. In this study, we compared the cellular iron uptake profiles of the brand (Ferrlecit® ) and generic sodium ferric gluconate (SFG) products...
December 15, 2017: Nanomaterials
https://www.readbyqxmd.com/read/29233512/response-to-oral-sucrosomial-iron-supplementation-in-patients-undergoing-bariatric-surgery-the-bari-fer-study
#13
Andreea Ciudin, Olga Simó-Servat, Jose Maria Balibrea, Ramon Vilallonga, Cristina Hernandez, Rafael Simó, Jordi Mesa
BACKGROUND: Chronic intravenous iron administration is often required after bariatric surgery. Oral sucrosomial iron has a particular form of absorption and may represent an alternative treatment. OBJECTIVE: To assess the effect of switching to oral sucrosomial iron in patients receiving intravenous iron supplementation after bariatric surgery. PATIENTS AND METHODS: A case-control study was conducted on 40 women of childbearing age, of whom 20 were switched to oral sucrosomial iron, while 20 patients continued on intravenous iron sucrose every three months...
January 2018: Endocrinología, Diabetes y Nutrición
https://www.readbyqxmd.com/read/29168243/iron-sucrose-assessing-the-similarity-between-the-originator-drug-and-its-intended-copies
#14
Tiziana Di Francesco, Erik Philipp, Gerrit Borchard
Iron sucrose (IS) is a complex nanocolloidal intravenous suspension used in the treatment of iron-deficiency anemia. Follow-on IS products (iron sucrose similars (ISSs)) have obtained marketing authorization by the generic pathway, implying that identical copies of IS may be manufactured. However, recent prospective and retrospective clinical studies showed discrepancies in clinical outcomes, which might be related to differences in physicochemical properties. The aim of this work is to measure and compare the physicochemical properties of IS and three ISSs available in the market using innovative analytical procedures...
November 2017: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/29075363/two-case-reports-of-desensitization-in-patients-with-hypersensitivity-to-iron
#15
Edgardo Chapman, Drixie Leal, Leidy Alvarez, Mónica Duarte, Elizabeth García
BACKGROUND: Iron deficiency anemia is a disease that can significantly compromise a patient's quality of life. Desensitization is a safe and effective treatment option for iron-deficient anemic patients who require intravenous iron despite their hypersensitivity to iron. This report describes a safe desensitization protocol for patients with iron hypersensitivity who require iron treatment for their clinical improvement. CASE PRESENTATION: Two patients of 20 and 46-year-old diagnosed with secondary iron deficiency anemia hipermenorreas and a clinical history of fail treatment with oral iron, who presented a reaction of the anaphylactic type while they receive iron parenteral sucrose...
2017: World Allergy Organization Journal
https://www.readbyqxmd.com/read/29032713/intravenous-iron-treatments-for-iron-deficiency-anemia-in-inflammatory-bowel-disease-a-budget-impact-analysis-of-iron-isomaltoside-1000-monofer-in-the-uk
#16
R F Pollock, G Muduma
Iron deficiency is the leading cause of anemia in patients with inflammatory bowel disease (IBD). Intravenous iron is the first-line treatment for clinically active IBD or previous oral iron intolerance. The aim of the present study was to develop a comparative model of iron deficiency and delivery for iron isomaltoside (IIM), ferric carboxymaltose (FCM), low molecular weight iron dextran (LMWID), and iron sucrose (IS) in the treatment of iron deficiency anemia associated with IBD. Areas covered: A model was developed to evaluate iron delivery characteristics, resource use and costs associated with IIM, FCM, LMWID and IS...
October 24, 2017: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/29027212/complexity-of-intravenous-iron-nanoparticle-formulations-implications-for-bioequivalence-evaluation
#17
REVIEW
Amy Barton Pai
Intravenous iron formulations are a class of complex drugs that are commonly used to treat a wide variety of disease states associated with iron deficiency and anemia. Venofer® (iron-sucrose) is one of the most frequently used formulations, with more than 90% of dialysis patients in the United States receiving this formulation. Emerging data from global markets outside the United States, where many iron-sucrose similars or copies are available, have shown that these formulations may have safety and efficacy profiles that differ from the reference listed drug...
November 2017: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/28921558/safety-and-efficacy-of-intravenous-iron-polymaltose-iron-sucrose-and-ferric-carboxymaltose-in-pregnancy-a-systematic-review
#18
REVIEW
Alaa Qassim, Ben W Mol, Rosalie M Grivell, Luke E Grzeskowiak
BACKGROUND: Intravenous (IV) iron in pregnancy is useful where oral iron is not tolerated or a rapid replenishment of iron is required. AIMS: To review the literature on the efficacy and safety of different IV iron preparations in the management of antenatal iron-deficiency anaemia (IDA). MATERIALS AND METHODS: We searched MEDLINE, Embase and Scopus from inception to June 2016. Eligible studies were randomised controlled trials (RCTs) and observational studies, involving administration of IV iron (ferric carboxymaltose (FCM), iron polymaltose (IPM) or iron sucrose (IS)), regardless of comparator, to manage antenatal IDA...
February 2018: Australian & New Zealand Journal of Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28886484/augmentation-of-intracellular-iron-using-iron-sucrose-enhances-the-toxicity-of-pharmacological-ascorbate-in-colon-cancer-cells
#19
Kristin E Brandt, Kelly C Falls, Joshua D Schoenfeld, Samuel N Rodman, Zhimin Gu, Fenghuang Zhan, Joseph J Cullen, Brett A Wagner, Garry R Buettner, Bryan G Allen, Daniel J Berg, Douglas R Spitz, Melissa A Fath
Pharmacological doses (> 1mM) of ascorbate (a.k.a., vitamin C) have been shown to selectively kill cancer cells through a mechanism that is dependent on the generation of H2 O2 at doses that are safely achievable in humans using intravenous administration. The process by which ascorbate oxidizes to form H2 O2 is thought to be mediated catalytically by redox active metal ions such as iron (Fe). Because intravenous iron sucrose is often administered to colon cancer patients to help mitigate anemia, the current study assessed the ability of pharmacological ascorbate to kill colon cancer cells in the presence and absence of iron sucrose...
April 2018: Redox Biology
https://www.readbyqxmd.com/read/28814833/markers-of-oxidative-nitrosative-stress-and-inflammation-in-lung-tissue-of-rats-exposed-to-different-intravenous-iron-compounds
#20
Jorge E Toblli, Gabriel Cao, Jorge F Giani, Fernando P Dominici, Margarita Angerosa
Iron deficiency anemia is a frequent complication in clinical conditions such as chronic kidney disease, chronic heart failure, inflammatory bowel disease, cancer, and excessive blood loss. Given the ability of iron to catalyze redox reactions, iron therapy can be associated with oxidative stress. The lung is uniquely susceptible to oxidative stress, and little is known about the effects of intravenous iron treatment in this organ. This study characterized changes in markers of oxidative/nitrosative stress and inflammation in the lung of non-iron deficient, non-anemic rats treated with five weekly doses (40 mg iron per kg body weight) of low molecular weight iron dextran (LMWID), iron sucrose (IS), ferric carboxymaltose (FCM), ferumoxytol (FMX), iron isomaltoside 1000 (IIM), or saline (control)...
2017: Drug Design, Development and Therapy
keyword
keyword
30008
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"